Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)for the Treatment of Myelodysplastic Syndromes (MDS)
This study has been completed.
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Gemin X )
First received: December 18, 2006
Last updated: August 16, 2013
Last verified: August 2013
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||November 2009|
|Primary Completion Date:||February 2009 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Received:||August 16, 2013|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Arellano ML, Borthakur G, Berger M, Luer J, Raza A. A phase II, multicenter, open-label study of obatoclax mesylate in patients with previously untreated myelodysplastic syndromes with anemia or thrombocytopenia. Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):534-9. doi: 10.1016/j.clml.2014.04.007. Epub 2014 Jun 12.